BACKGROUND: This study examines the association between microalbuminuria and the development of proteinuria among HIV-infected persons. METHODS: A total of 948 subjects provided urine samples for albumin, protein and creatinine measurements semiannually. Microalbuminuria was defined as an albumin-to-creatinine ratio of >30 mg/g. Proteinuria was defined as a protein-to-creatinine ratio of > or =0.350 mg/mg. The progression from microalbuminuria to proteinuria was described. RESULTS: At baseline, 69.4% of the subjects had no detectable proteinuria, 20.2% had microalbuminuria, and 10.4% had proteinuria. Subjects with microalbuminuria and proteinuria were more likely to be black (P=0.02), have lower CD4 cell counts (P=0.02 comparing subjects without abnormal urine protein excretion to subjects with microalbuminuria; P=0.0001 comparing subjects with microalbuminuria to subjects with proteinuria), and have a higher HIV RNA level (P=0.08 and 0.04, respectively). Among 658 subjects with normal urine protein, 82.7% continued to have no abnormality, 14.3% developed microalbuminuria, and 3.0% developed proteinuria. Subjects without baseline proteinuria (i.e. either normal protein excretion or microalbuminuria) who developed proteinuria were more likely to have microalbuminuria (P=0.001), a lower CD4 cell count (P=0.06), and a higher plasma HIV RNA (P=0.03) than those who did not progress to proteinuria. In multivariate analysis, only microalbuminuria remained associated with the development of proteinuria (odds ratio 2.9; 95% confidence interval 1.5, 5.5; P=0.001). CONCLUSION: Microalbuminuria predicts the development of proteinuria among HIV-infected persons. Because proteinuria has been linked to poorer outcomes, strategies to affect microalbuminuria should be tested.
BACKGROUND: This study examines the association between microalbuminuria and the development of proteinuria among HIV-infectedpersons. METHODS: A total of 948 subjects provided urine samples for albumin, protein and creatinine measurements semiannually. Microalbuminuria was defined as an albumin-to-creatinine ratio of >30 mg/g. Proteinuria was defined as a protein-to-creatinine ratio of > or =0.350 mg/mg. The progression from microalbuminuria to proteinuria was described. RESULTS: At baseline, 69.4% of the subjects had no detectable proteinuria, 20.2% had microalbuminuria, and 10.4% had proteinuria. Subjects with microalbuminuria and proteinuria were more likely to be black (P=0.02), have lower CD4 cell counts (P=0.02 comparing subjects without abnormal urine protein excretion to subjects with microalbuminuria; P=0.0001 comparing subjects with microalbuminuria to subjects with proteinuria), and have a higher HIV RNA level (P=0.08 and 0.04, respectively). Among 658 subjects with normal urine protein, 82.7% continued to have no abnormality, 14.3% developed microalbuminuria, and 3.0% developed proteinuria. Subjects without baseline proteinuria (i.e. either normal protein excretion or microalbuminuria) who developed proteinuria were more likely to have microalbuminuria (P=0.001), a lower CD4 cell count (P=0.06), and a higher plasma HIV RNA (P=0.03) than those who did not progress to proteinuria. In multivariate analysis, only microalbuminuria remained associated with the development of proteinuria (odds ratio 2.9; 95% confidence interval 1.5, 5.5; P=0.001). CONCLUSION: Microalbuminuria predicts the development of proteinuria among HIV-infectedpersons. Because proteinuria has been linked to poorer outcomes, strategies to affect microalbuminuria should be tested.
Authors: E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245
Authors: Garabed Eknoyan; Thomas Hostetter; George L Bakris; Lee Hebert; Andrew S Levey; Hans-Henrik Parving; Michael W Steffes; Robert Toto Journal: Am J Kidney Dis Date: 2003-10 Impact factor: 8.860
Authors: Lynda A Szczech; Elizabeth T Golub; Gayle Springer; Michael Augenbraun; Mary Young; Monica Gandhi; Barbara S Gillepsie; Kathryn Anastos Journal: J Acquir Immune Defic Syndr Date: 2008-07-01 Impact factor: 3.731
Authors: Lynda Anne Szczech; Stephen J Gange; Charles van der Horst; John A Bartlett; Mary Young; Mardge H Cohen; Kathryn Anastos; Preston S Klassen; Laura P Svetkey Journal: Kidney Int Date: 2002-01 Impact factor: 10.612
Authors: Lytt I Gardner; Scott D Holmberg; John M Williamson; Lynda A Szczech; Charles C J Carpenter; Anne M Rompalo; Paula Schuman; Robert S Klein Journal: J Acquir Immune Defic Syndr Date: 2003-02-01 Impact factor: 3.731
Authors: Kasper Rossing; Per K Christensen; Peter Hovind; Lise Tarnow; Peter Rossing; Hans-Henrik Parving Journal: Kidney Int Date: 2004-10 Impact factor: 10.612
Authors: Jose M Miro; Federico Cofan; Joan C Trullas; Christian Manzardo; Carlos Cervera; Montserrat Tuset; Federico Oppenheimer; Mercedes Brunet; Asuncion Moreno; Josep M Campistol; Jose M Gatell Journal: Curr HIV/AIDS Rep Date: 2012-09 Impact factor: 5.071
Authors: Elizabeth L Yanik; Gregory M Lucas; David Vlahov; Gregory D Kirk; Shruti H Mehta Journal: Clin J Am Soc Nephrol Date: 2010-08-12 Impact factor: 8.237
Authors: Colleen Hadigan; Elizabeth Edwards; Alice Rosenberg; Julia B Purdy; Estee Fleischman; Lilian Howard; JoAnn M Mican; Karmini Sampath; Akinbowale Oyalowo; Antoinette Johnson; Alexandra Adler; Catherine Rehm; Margo Smith; Leon Lai; Jeffrey B Kopp Journal: Am J Nephrol Date: 2013-04-20 Impact factor: 3.754
Authors: Pichaya O-charoen; Lishomwa C Ndhlovu; Louie Mar A Gangcuangco; Sheila M Keating; Philip J Norris; Roland C K Ng; Brooks I Mitchell; Cecilia M Shikuma; Dominic C Chow Journal: AIDS Res Hum Retroviruses Date: 2014-12 Impact factor: 2.205
Authors: Brooks I Mitchell; Mary Margaret Byron; Roland C Ng; Dominic C Chow; Lishomwa C Ndhlovu; Cecilia M Shikuma Journal: PLoS One Date: 2016-04-20 Impact factor: 3.240